Ilya Pharma has appointed Leo Groenewegen as CEO of its recent acquisition Nordic Bioanalysis.
Founded in 2010, Nordic Bioanalysis (NBAB) have established a strong reputation both in the Nordics and internationally as experts in bioanalytical development and validation for pharmaceuticals, classic small molecules and biologics including antibodies as well as Advanced Therapy Medicinal Products (ATMPs) and Gene Therapy Medicinal Products (GTMPs), describes Ilya Pharma in a press release.
“Nordic Bioanalysis AB was highly profitable with a +50% RoE last year, now we have redirected those funds into both Nordic and international growth of the company. This year, the objective is to double its revenue and size of the operational team. We are delighted to bring Leo on board to steer this growth, starting with the European markets, whilst preserving and refining the agility and flexibility – traits that companies in the rapidly evolving biologics, ATMP, CGT and LPB pipeline rely on for their success to clinical validation and product development,” says Oskar Lund, Ilya Pharma CFO & Chairman of the Board for NBAB.
Leo Groenewegen brings experience in the field having worked for a diverse range of companies including IMS health (IQVIA), NextCell Pharma, Orange Light Ventures and most recently CellulaREvolution, which he co-founded and expanded. He is now tasked with expanding NBAB’s already significant customer base which ranges from big pharma to start ups entering the regulated product development and validation phases in pharmaceuticals, including ATMP/GTMPs, Cell and Gene Therapies (CGTs) and medical devices, as well as other live bacterial products (LBPs).
“I am delighted to join NBAB at this next stage of their development. The team is extremely agile, flexible, cost efficient and dedicated to the success of their customers, lead times are extremely competitive. These are also exciting times in the ATMP field with all the new modalities in cell- and gene therapy, microbial based therapeutics, LBP and more, where having a reliable and agile partner for development and validation of bioassays is one of the main keys to success in clinical proof of concept. I hope my broad experience in bioprocessing field will help us reach the ambitious targets we have set,” says Leo Groenewegen, CEO NBAB.
Photo of Leo Groenewegen and Oskar Lund